Zydus Lifesciences Limited
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.
Key Business
- NCE RESEARCH
- BIOLOGICS
- VACCINES
Shareholding Pattern
-PUBLIC GROUP
-PROMOTER GROUP
Financial Summary
| Particulars | March 2024 | March 2023 | March 2022 |
| Sales | 19,547 | 17,237 | 15,110 |
| Sales Growth % | 13.40% | 14.08% | 4.90% |
| Expenses | 14,163 | 13,378 | 11,768 |
| Operating Profit | 5,384 | 3,860 | 3,342 |
| OPM % | 28% | 22% | 22% |
| Net Profit | 3,973 | 2,092 | 4,618 |
| EPS in Rs | 38.36 | 19.37 | 43.83 |
Synopsis of Financials
- Consolidated revenues for Q1 FY25 stood at ₹62.1 billion, reflecting a 21% year-on-year (YoY) growth and a 12% quarter-on-quarter (QoQ) growth.
- EBITDA for the quarter was ₹20.8 billion, marking a 38% YoY increase and a 28% QoQ increase.
- EBITDA margin improved to 33.6%, up 430 basis points YoY and 410 basis points QoQ.
- Net profit reached ₹14.2 billion, up 31% YoY and 20% QoQ.
Final Outlook
Zydus Lifesciences Ltd is currently in a strong uptrend, driven by robust financial performance and strategic growth in key markets. The company’s stock is likely to continue its positive trajectory unless significantly impacted by global economic downturns or geopolitical instability. Investors should watch for any signs of weakening in the US market, given its importance to Zydus’ revenue, as well as potential volatility from global events. The company has displayed commendable growth in Q1 FY25. However, it is trading at its all time high; therefore investors are recommended to hold the stock for future returns.
Earnings Reports: The major breakouts likely correspond with strong earnings reports or positive forward guidance from the company. Pharmaceutical companies often experience significant price movements based on drug approvals, partnerships, or positive clinical trial results.
FDA Approvals/Clinical Trial Results: Given that Zydus Lifesciences is a pharmaceutical company, any positive results from clinical trials or FDA approvals could have been a catalyst for the price movements.
Zydus-Lifescience-Ltd